QIVIGY Expansion Capitalize on the QIVIGY launch and Kedrion's growing limited distribution network to broaden access for adults with Primary Humoral Immunodeficiency. Target ambulatory infusion centers and specialty distributors (for example My Local Infusion, Mylocalinfusion, AOM Infusion) and collaborate with AvevoRx to scale high touch IVIG delivery.

Manufacturing Capacity Kedrion's investment in the Garfagnana facility and the 2022 merger with Bio Products Laboratory position the company to scale plasma derived therapies globally. This creates opportunities to secure long term manufacturing partnerships with hospitals and regional distributors seeking reliable supply for rare disease medicines.

Supply Chain Partnerships A strategic procurement focus is seen with the JAGGAER partnership and a formalized distribution network. This enables business development teams to offer end to end supply chain solutions, optimize inventory at infusion centers, and pursue preferred supplier status for plasma derived products.

Patient Access Alliances Kedrion's rare connections philosophy and collaborations with medical communities and patient advocacy groups create openings for co developed patient access programs, clinical support initiatives, and payer engagement to widen coverage of plasma derived therapies.

Portfolio Synergy With a broad portfolio of 38 medicines and a growing QIVIGY line, there are cross selling opportunities to hospitals and infusion centers, enabling upsell into PI patients and other rare disease cohorts through existing relationships.